shutterstock_1395147236_poptika
Poptika / Shutterstock.com
15 December 2020Big PharmaSally Shorthose and Rumana Khanom

What 2020 means for the life sciences

2020 has been a tumultuous year in many respects and the conflation of a pandemic and the impact of the UK’s departure from the EU has profound implications for the life sciences and medical devices industries in the UK and the EU. In this article, we consider how and why these events will have such an effect and how affected businesses may need to prepare for these.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
11 February 2026   Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.
Big Pharma
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.